Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,152Revenue $M54.8Net Margin (%)-142.9Z-Score2.0
Enterprise Value $M1,054EPS $-0.7Operating Margin %-135.9F-Score3
P/E(ttm))0Cash Flow Per Share $-0.2Pre-tax Margin (%)-142.9Higher ROA y-yN
Price/Book21.110-y EBITDA Growth Rate %0Quick Ratio5.3Cash flow > EarningsY
Price/Sales18.55-y EBITDA Growth Rate %-16.9Current Ratio5.5Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-60.2Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)2ROE % (ttm)-383.3Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M125ROI % (ttm)-92.5Gross Margin Increase y-yN

Gurus Latest Trades with HALO

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
Current Price Change from Average Comment Current Shares
HALOJean-Marie Eveillard 2014-06-30 Add0.03%$7.09 - $12.31
$ 9.2610%Add 94.94%2,795,080
HALOJohn Burbank 2014-06-30 Add$7.09 - $12.31
$ 9.2610%Add 55.47%24,523
HALOJohn Burbank 2014-03-31 Buy 0.01%$12.11 - $17.57
$ 9.26-38%New holding, 15773 sh.15,773
HALOJean-Marie Eveillard 2013-12-31 Buy 0.05%$9.66 - $15.7
$ 9.26-28%New holding, 1294580 sh.1,294,580
HALOJohn Burbank 2012-12-31 Sold Out -0.17%$4.82 - $7.07
$ 9.2659%Sold Out0
HALOJohn Burbank 2012-09-30 Add0.07%$4.28 - $9.78
$ 9.2627%Add 66.67%500,000
HALOJohn Burbank 2012-06-30 Add0.03%$7.32 - $13
$ 9.266%Add 50%300,000
HALOJohn Burbank 2012-03-31 Buy 0.09%$9.22 - $13.35
$ 9.26-12%New holding, 200000 sh.200,000
HALOGeorge Soros 2011-12-31 Sold Out -0.0018%$5.72 - $9.73
$ 9.2613%Sold Out0
HALOGeorge Soros 2011-09-30 Buy $5.62 - $7.29
$ 9.2640%New holding, 17100 sh.17,100
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

HALO is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
HALO Jean-Marie Eveillard 2014-06-302,795,0802.240.07+94.94%
HALO John Burbank 2014-06-3024,5230.020+55.47%
Premium Most recent portfolio changes are included for Premium Members only!

HALO: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Torley HelenPresident and CEO 2014-09-16Buy50,000$8.926.73view
RAMSAY DAVID AVP and CFO 2014-09-16Buy25,000$8.96.97view
PATTON JOHN STUARTDirector 2014-08-19Sell75,000$9.96-4.42view
Engler RobertDirector 2014-08-14Sell35,000$9.96-4.42view
Engler RobertDirector 2014-05-15Sell126,700$7.5625.93view
PATTON JOHN STUARTDirector 2013-09-16Sell75,000$9.134.27view
Shepard H. MichaelVP, Chief Scientific Officer 2013-08-19Sell10,000$7.1133.9view
FALBERG KATHRYN EDirector 2013-08-14Buy100,000$6.8239.59view
Engler RobertDirector 2012-11-29Buy15,000$5.5770.92view
Shaffer James PVP & Chief Commercial Officer 2012-11-14Buy20,000$5.2282.38view

Press Releases about HALO :

    Quarterly/Annual Reports about HALO:

      News about HALO:

      Articles On GuruFocus.com
      Insider Buys at Halozyme Look to Improve Stock Outlook Sep 18 2014 
      comment on HALO May 12 2013 
      comment on HALO May 12 2013 
      comment on HALO May 12 2013 
      Halozyme Therapeutics Inc. Reports Operating Results (10-Q) Aug 06 2010 
      Halozyme Therapeutics Inc. Reports Operating Results (10-Q) May 07 2010 
      Halozyme Therapeutics Inc. Reports Operating Results (10-Q) Nov 06 2009 
      Halozyme Therapeutics Reports Second Quarter 2009 Financial Results Aug 07 2009 
      Halozyme Therapeutics Inc. Reports Operating Results (10-Q) Aug 07 2009 
      Halozyme to Host Conference Call and Webcast on August 7 to Discuss Second Quarter 2009 Financial Re Jul 31 2009 

      More From Other Websites
      Halozyme's PEGPH20 Study S1313 Clinical Hold Lifted by FDA Sep 19 2014
      Insider Buys at Halozyme Look to Improve Stock Outlook Sep 18 2014
      SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For... Sep 18 2014
      Halozyme Therapeutics (HALO) Jumps: Stock Up 9.3% Sep 18 2014
      FDA Approves Baxter’s HYQVIA for Treatment of Adults with Primary Immunodeficiency Sep 12 2014
      Why You Shouldn't Bet Against Halozyme Therapeutics (HALO) Stock Sep 08 2014
      Halozyme's PEGPH20 Program In Metastatic Pancreatic Cancer Receives Fast Track Designation Sep 03 2014
      HALOZYME THERAPEUTICS INC Financials Aug 19 2014
      Halozyme Gains on Narrower-than-Expected Loss, Revenues Up Aug 14 2014
      HALOZYME THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 11 2014
      Halozyme Reports Second Quarter 2014 Financial Results Aug 11 2014
      Q2 2014 Halozyme Therapeutics, Inc. Earnings Release - After Market Close Aug 11 2014
      Halozyme to Host second Quarter 2014 Financial Results Conference Call Aug 04 2014
      Trade-Ideas: Halozyme Therapeutics (HALO) Is Today's "Perilous Reversal" Stock Aug 01 2014
      Halozyme Therapeutics Receives Favorable FDA Decision Jul 31 2014
      FDA Advisory Committee Panel Provides Favorable Recommendation on Baxter’s HyQvia for Primary... Jul 31 2014
      FDA panel: Benefit of Baxter's immune therapy outweighs risk Jul 31 2014
      Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer Jul 22 2014
      Trade-Ideas: Halozyme Therapeutics (HALO) Is Today's "Perilous Reversal" Stock Jul 21 2014
      BUZZ-U.S. Stocks on the Move-Isle of Capri, Intercloud, Rent-A-Center Jul 11 2014

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial